http://www.mjsite.com saves this page so readers can view old news that may not still be availible elsewhere.
This is a saved page of Hana Biosciences initiates phase I study of SEV in tumour patient (PharmaBiz)
This is a copy we made of the page on 14-Aug-2006.
The original page may or may not still be availible and pictures and text may have changed since then.
Click Here to view the original page at the original website.

Hana Biosciences initiates phase I study of SEV in tumour patient - Clinical Trials

Tuesday, August 15, 2006		Feedback \| Helpdesk \| Login

EDITORIAL

PURCHASE PREFERENCE POLICY

past editorials ...

SERVICES

Tenders&Enquiries

Notifications

Pharma Regulations

Patent Laws and Amendments

Patent Scan

Documents

New Drug Approvals

Import Reg. Update

Notified Prices

Company Profiles

Pharmabiz Studies of Top Companies

Corporate X-ray

Pharma Projects

Indian Cos Approved by Intl Regulatory Agencies

Drug Export Procedures

Drug Registration Norms for Various Countries

Pharma Export Data

Govt Recognised In-House R&D Units

AICTE Boards & Committees

List of banned FDCs w.e.f. 01.01.2002

List of formulations containing PPA

List of FDCs of Rifampicin + Isoniazid

List of Indian CROs

List of CROs (International)

US FDA: Warnings

US FDA: Approved NMEs upto November 2005

US FDA: New Approvals

US approved Labs with Stem Cell Lines

Govt & approved labs of India

Archives: News & Features

SPECIAL FEATURES

Features

INTERVIEW

"India is going to be a competitor in biotech research and not just a collaborator"
Dr Simon Best, the founder and present non-executive chairman of the Edinburgh-based Ardana Bioscience is also the chairman of Bio Industry Association (BIA) UK.

past interviews ...

Clinical Trials

Hana Biosciences initiates phase I study of SEV in tumour patient

Saturday, August 05, 2006 10:00 IST
South San Francisco

Hana Biosciences, a biopharmaceutical company focused on advancing cancer care, has announced the initiation of a phase I clinical study of Sphingosome Encapsulated Vinorelbine (SEV) in patients with advanced solid tumours.

Read complete story ...
(You will need to login first to read this story.)